Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus. Favipiravir is an orally administrable antiviral drug whose mechanism of action is to selectively inhibit RNA-dependent RNA polyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinkai, Masaharu, Tsushima, Kenji, Tanaka, Shingo, Hagiwara, Eri, Tarumoto, Norihito, Kawada, Ichiro, Hirai, Yuji, Fujiwara, Sho, Komase, Yuko, Saraya, Takeshi, Koh, Hidefumi, Kagiyama, Naho, Shimada, Megumi, Kanou, Daiki, Antoku, Shinichi, Uchida, Yujiro, Tokue, Yutaka, Takamori, Mikio, Gon, Yasuhiro, Ie, Kenya, Yamazaki, Yoshitaka, Harada, Kazumasa, Miyao, Naoki, Naka, Takashi, Iwata, Mitsunaga, Nakagawa, Atsushi, Hiyama, Kazutoshi, Ogawa, Yoshihiko, Shinoda, Masahiro, Ota, Shinichiro, Hirouchi, Takatomo, Terada, Jiro, Kawano, Shuichi, Ogura, Takashi, Sakurai, Tsutomu, Matsumoto, Yoshihiko, Kunishima, Hiroyuki, Kobayashi, Osamu, Iwata, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396144/
https://www.ncbi.nlm.nih.gov/pubmed/34453234
http://dx.doi.org/10.1007/s40121-021-00517-4

Ejemplares similares

Ejemplares similares